CHANGE HEALTHCARE CANADA COMPANY recalls Horizon Cardiology Hemo. Version 12.2.

Recall date

August 21, 2024

Source

U.S. Food & Drug Administration (FDA) — enforcement report

Recall number

Z-0127-2025

FDA classification

Class II

Brand / firm

CHANGE HEALTHCARE CANADA COMPANY

Sold / distributed

Worldwide distribution - US Nationwide and the countries of Australia, Canada, Germany, Ireland, Israel, United Kingdom.

Why it was recalled

A potential issue has been identified in Change Healthcare Cardiology Hemo where incorrect data entry can lead to inaccurate hemodynamic calculations, potentially resulting in misdiagnosis and inappropriate treatment. This issue occurs when the unit of measurement (UOM) for hemoglobin is configured in a way that differs from the users understanding.

Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What was recalled

Horizon Cardiology Hemo. Version 12.2.